Canadian cannabis company Aurora Cannabis Inc.’s public appeal pertaining to its German cannabis production tender has been completed and that its contract with Germany’s Federal Institute for Drugs and Medical Devices has been finalized.
This means that the Canadian firm is allowed to start the construction of its new, state-of-the-art indoor medical marijuana production facility in Leuna, Germany next month. Aurora Cannabis expects that this project will be completed within a year from groundbreaking.
Moreover, Aurora anticipates that the initial shipments of German-grown cannabis will become available to medical patients in the European country beginning October 2020. The new facility is estimated to produce at least 4,000 kilograms of medical cannabis products over a period of four years. This yield will be expanded over time as German regulations allow.
According to Dr. Axel Gille, Aurora Europe’s managing director, they had focused their proposal on implementing the company’s standard, pharmaceutical-grade cultivation techniques. And they did this while also leveraging the broad competencies of their professional team, including their pharmacists, architects, plant specialists, engineers, and project managers.
Gille added that the construction of Aurora’s Leuna facility is the next logical step in the expansion of their Europe-wide production network. Setting up this facility will help ensure that qualified patients have safe access to consistent, high-quality medical marijuana buds and extracts.